Overview
- The companies disclosed a co-development and licensing agreement that Butterfly first flagged in an SEC filing and that could pay Butterfly up to $74 million over five years.
- Midjourney showed a prototype Midjourney Scanner that uses about 40 of Butterfly’s Ultrasound‑on‑Chip modules per unit and says future models will use more modules as the design scales.
- The announcement, reported Thursday, sent Butterfly shares up roughly 31% to a 52‑week intraday high as short positions covered and social interest amplified the move.
- Wall Street analysts praised the licensing validation as proof the chip business can stand alone but raised three key uncertainties: the FDA pathway for a new imaging platform, whether insurers will reimburse routine whole‑body scans, and whether clinical data will show clear patient benefit.
- If Midjourney hits its target of 50,000+ scanners by 2031, William Blair estimated that demand could translate into millions of Butterfly chips, but near‑term commercial success depends on regulatory approvals, reimbursement decisions, and clinical proof that the scanner improves care.